Matinas BioPharma (MTNB) stock price, revenue, and financials

Matinas BioPharma market cap is $141.5 m, and annual revenue was $89.81 k in FY 2019

$141.5 M

MTNB Mkt cap, 27-Mar-2020

$89.8 K

Matinas BioPharma Revenue FY, 2019
Matinas BioPharma Net income (FY, 2019)-17.4 M
Matinas BioPharma EBIT (FY, 2019)-18.9 M
Matinas BioPharma Cash, 31-Dec-201922.2 M
Matinas BioPharma EV123.5 M

Matinas BioPharma Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.6m3.2m4.1m7.3m12.4m22.2m

Prepaid Expenses

114.4k231.8k304.4k502.0k538.6k1.9m

Current Assets

2.8m3.6m4.6m8.0m13.1m29.9m

PP&E

340.0k377.7k356.1k1.6m2.0m1.7m

Goodwill

1.3m1.3m1.3m1.3m1.3m

Total Assets

3.4m8.4m9.8m14.4m19.9m40.2m

Accounts Payable

271.2k497.8k475.6k582.9k295.7k679.3k

Dividends Payable

1.2m

Short-term debt

44.4k11.3k128.0k197.2k283.1k423.7k

Current Liabilities

1.1m1.1m1.4m2.2m2.8m3.1m

Long-term debt

15.3k16.4k67.7k107.7k3.8m

Non-Current Liabilities

961.6k4.1m

Total Debt

59.7k11.3k118.0k170.2k199.8k4.2m

Total Liabilities

1.1m2.3m2.7m3.7m3.8m7.2m

Common Stock

3.2k5.7k5.8k9.3k11.3k16.3k

Preferred Stock

6.1m

Additional Paid-in Capital

16.3m29.3m36.2m56.2m72.3m113.4m

Retained Earnings

(14.1m)(23.2m)(35.2m)(51.3m)(65.9m)(84.4m)

Total Equity

2.2m6.1m7.1m10.7m16.1m33.1m

Debt to Equity Ratio

0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x

Financial Leverage

1.5 x1.4 x1.4 x1.4 x1.2 x1.2 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

8.6m6.6m5.0m4.6m6.6m4.4m1.7m578.3k6.2m15.8m11.3m9.0m4.3m8.9m6.6m39.4m36.8m32.7m

Accounts Receivable

89.8k

Prepaid Expenses

87.6k38.1k108.1k93.6k115.0k342.2k138.0k139.6k254.0k803.0k317.3k1.0m475.3k249.8k692.4k391.0k494.6k1.4m

Current Assets

8.6m6.7m5.1m4.8m6.9m4.9m1.9m773.5k6.5m16.8m11.7m10.2m4.9m9.3m7.5m39.9m37.4m34.3m

PP&E

364.9k361.6k357.7k339.0k363.2k365.5k364.8k382.5k368.8k344.2k1.2m1.5m1.7m1.8m2.1m1.5m1.8m1.8m

Goodwill

1.4m1.4m1.4m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m

Total Assets

9.3m7.4m5.8m9.8m11.9m9.9m6.7m5.6m11.3m22.0m17.8m16.5m11.5m16.0m14.4m50.6m48.2m44.8m

Accounts Payable

242.3k281.1k211.8k466.6k745.6k282.1k620.6k475.9k209.5k1.2m453.2k341.6k473.5k497.4k303.4k394.7k548.1k685.8k

Dividends Payable

1.2m1.2m1.2m

Short-term debt

44.5k43.8k44.1k44.6k33.6k32.5k9.6k198.6k57.4k18.8k316.9k94.3k52.7k403.1k79.9k

Current Liabilities

673.4k872.2k1.0m1.3m1.1m872.8k1.3m1.3m1.4m2.0m1.3m1.9m1.0m1.5m2.6m3.1m3.5m2.6m

Long-term debt

43.6k33.6k22.5k20.7k19.0k13.8k51.4k47.9k116.0k103.0k122.6k4.1m4.0m3.9m

Non-Current Liabilities

4.5m4.3m4.2m

Total Debt

88.2k77.4k66.5k44.6k10.0k32.5k30.3k188.9k47.2k70.1k297.9k42.6k155.7k319.7k79.9k4.0m3.9m

Total Liabilities

717.0k905.8k1.0m3.4m3.2m2.9m2.5m2.6m2.6m3.2m2.6m3.7m3.1m3.5m4.1m7.6m7.8m6.8m

Common Stock

3.2k3.2k3.2k4.7k5.7k5.7k5.8k5.8k5.8k9.1k9.2k9.3k9.4k9.4k9.8k14.3k14.4k16.3k

Preferred Stock

6.1m6.0m

Additional Paid-in Capital

14.6m14.8m15.7m23.0m27.6m28.1m29.6m30.0m35.9m52.5m53.0m54.7m58.2m58.8m60.9m103.3m104.6m112.7m

Retained Earnings

(6.0m)(8.4m)(11.0m)(16.6m)(19.0m)(21.2m)(25.4m)(27.1m)(33.3m)(39.7m)43.6m(47.6m)(55.4m)(58.8m)(62.3m)(70.0m)(73.8m)(78.8m)

Total Equity

8.6m6.5m4.7m6.4m8.6m7.0m4.2m3.0m8.7m18.9m15.2m12.8m8.4m12.5m10.3m43.0m40.4m38.0m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.1 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.1 x

Financial Leverage

1.1 x1.1 x1.2 x1.5 x1.4 x1.4 x1.6 x1.9 x1.3 x1.2 x1.2 x1.3 x1.4 x1.3 x1.4 x1.2 x1.2 x1.2 x

Matinas BioPharma Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.2m)(9.1m)(7.6m)(15.5m)(14.1m)(17.4m)

Depreciation and Amortization

41.6k43.5k52.6k100.6k218.3k206.0k

Accounts Payable

(125.6k)(73.7k)(22.2k)107.3k(287.2k)383.7k

Cash From Operating Activities

(8.0m)(7.8m)(6.1m)(11.5m)(10.3m)(14.1m)

Purchases of PP&E

(288.5k)(76.2k)(942.2k)(535.9k)(405.6k)

Cash From Investing Activities

(288.5k)(5.4k)(942.2k)(535.9k)(6.0m)

Short-term Borrowings

(10.0k)(144.3k)(330.8k)(370.1k)(199.8k)

Long-term Borrowings

(48.4k)(15.9k)(17.1k)(59.2k)(81.7k)

Cash From Financing Activities

8.5m7.0m15.6m15.9m29.9m

Net Change in Cash

(8.2m)636.3k878.5k3.2m5.0m9.7m

Matinas BioPharma Ratios

USDY, 2019

EV/EBIT

-6.5 x

EV/CFO

-8.8 x

Revenue/Employee

6.0k

Financial Leverage

1.2 x